IVF and Age Limits: Realistic Success Rates and Boundaries After 40
Key Takeaways
Maternal age is one of the strongest biological predictors of IVF outcome with a patient’s own eggs. Treatment after 40 may still be considered, but the chance of live birth declines as age rises and is not determined by follicle count alone. A sound decision uses clearly defined registry measures, ovarian-reserve assessment, and agreed stopping points.
Key evidence: SART — National Summary Report on Age & ART Outcomes (2022) ASRM — Testing and Interpreting Measures of Ovarian Reserve (2020) ASRM — PGT-A Committee Opinion (2024)
Age is one of the strongest biological factors affecting IVF with a patient’s own eggs. ASRM’s ovarian-reserve opinion explains why ovarian-reserve markers should not be treated as a substitute for age. Many women and couples in their 40s want to know whether treatment is still reasonable to consider, what the chance of live birth may be, and when another cycle may no longer be worthwhile.
After 40, those questions need clear definitions rather than a single headline percentage. The useful starting points are the patient’s ovarian reserve, the age-related risk of chromosomal abnormalities, the clinic’s outcome definitions, and an agreed plan for when to stop.
The Core Question: Is There a Strict Age Limit for IVF?
There is no single international age cut-off that applies to every clinic. However, the chance of success with a patient’s own eggs generally declines with age, with a sharper fall in older age groups.
The main biological issues are the age-related rise in chromosomal abnormalities and the decline in the number of remaining follicles. These affect different parts of the IVF process and should not be reduced to one AMH value.
Ovarian Reserve vs. Egg Quality: The Vital Distinction
A common question is whether AMH tells us about egg quality. It does not. AMH and AFC mainly help estimate ovarian response and the number of oocytes that may be retrieved, while chromosomal competence is strongly related to age. ASRM’s ovarian-reserve opinion
- Ovarian reserve (AMH and antral follicle count, or AFC): These markers help estimate how many follicles may respond to stimulation. They are useful for predicting oocyte yield, but they are poor independent predictors of reproductive potential.
- Chromosomal competence: Age strongly influences the likelihood that an embryo will have the expected chromosome number. A higher AMH may provide more oocytes to work with, but it does not guarantee a euploid embryo or reverse age-related changes in the eggs. The reported proportion of aneuploid embryos varies by study design, laboratory, and the population examined. Age-related aneuploidy study
A higher AMH at 43 or 44 may increase the number of oocytes retrieved, but it does not reverse the biological age of those oocytes.
IVF Live Birth Rates by Age: What the Registries Show
When evaluating success, registry data are more useful than a clinic headline, but only if the age group and denominator are clear. The 2022 SART national report reports live births per intended egg retrieval using the patient’s own eggs, with embryo transfers included during the follow-up period.
The report does not split the oldest group into 43–44 and 45+; it uses the published age bands below:
| SART age group | Live birth per intended egg retrieval, patient’s own eggs |
|---|---|
| 41–42 years | 13.0% |
| More than 42 years | 4.5% |
These figures are national averages, not an individual prognosis. They also cannot, by themselves, establish separate live-birth rates for ages 43–44 and 45+. Other registries report different age bands and endpoints, so the source population and denominator should always be shown.
The Role and Limitations of PGT-A After 40
Preimplantation Genetic Testing for Aneuploidy (PGT-A) is often discussed in later reproductive age. It can provide information about chromosome copy number in an embryo, but it does not remove the biological limits of the eggs or guarantee a live birth.
- What PGT-A does: It biopsies trophectoderm cells from a day-5 or day-6 blastocyst to estimate chromosome copy-number status. Retrospective studies in women aged 40–43 have reported implantation rates around 50% for euploid embryos, but that estimate applies only after a euploid embryo is available and is not a universal rate for every patient or laboratory. ASRM’s 2024 PGT-A opinion
- What PGT-A cannot do: It cannot correct an abnormal embryo or create a healthy embryo. It also does not guarantee implantation, pregnancy, or live birth.
- The challenge when embryo numbers are low: Some patients over 42 produce few oocytes and may have only one or two blastocysts available. If all embryos are reported as aneuploid, there may be no embryo to transfer. The decision to test should therefore consider the expected number of embryos, laboratory practice, cost, and the patient’s goals.
In patients with very few embryos, the decision to use PGT-A or proceed with an unbiopsied fresh or frozen embryo transfer should be discussed with the treating fertility physician.
Regulatory and Legal Context in Turkey
For international patients considering treatment in Türkiye, the assisted-reproduction framework and current health-tourism rules should be checked separately. ST-1008 identifies the clinic’s international health-tourism authorization; it is not itself the rule governing embryo transfer or gamete eligibility.
- Autologous gametes: Under the Turkish assisted-reproduction framework, treatment is restricted to the couple’s own eggs and sperm. Donor eggs, donor sperm, and surrogacy are not available within this framework.
- Embryo-transfer limits: The regulation states that patients aged 35 and older may receive up to two embryos. For patients under 35, the first two applications are limited to one embryo; later applications may allow up to two. The current rule and the patient’s application history should be confirmed with the authorised centre.
- Upper-age question: The regulation text cited here does not state one simple upper-age ceiling for own-egg IVF. That does not mean treatment is appropriate at every age: current eligibility, medical safety, and informed consent still have to be assessed.
Dr. Aksoy’s Approach: Medical Realism and Setting Boundaries
At later reproductive ages, a useful consultation does two things: it explains the limits honestly and gives the patient a clear way to decide whether to continue.
Baseline Evaluation (AMH, AFC, Medical History)
│
▼
Evidence-Based Discussion of Individualised Odds
│
▼
Agreed Trial Plan with Defined Stopping Points
│
┌─────────────┴─────────────┐
▼ ▼
Follicular Response No Response /
& Blastocyst Development No Euploid Embryo After Repeated Attempts
│ │
▼ ▼
Transfer Plan if Appropriate Stop and Discuss
Other OptionsDr. Senai Aksoy focuses on agreeing the stopping points before stimulation begins:
- Before medication: We review the patient’s AMH, antral follicle count, medical history, and previous stimulation response. When the individualized estimate is very low, we explain what it means and how uncertain it remains.
- If the patient chooses a trial: The plan should specify how many attempts are reasonable and which findings would change the plan. Stimulation protocol is individualized; no protocol can reverse age-related chromosomal changes.
- When to stop: No follicular response, poor fertilization, or repeated failure to develop a transferable embryo may be reasons to reconsider another cycle. Repeating the same approach without a new rationale can add physical, emotional, and financial burden.
- Maternal health: Pregnancy after 40 is associated with higher risks of hypertension, preeclampsia, gestational diabetes, and caesarean delivery. Pre-conception assessment should therefore include the patient’s cardiovascular and metabolic health. ACOG guidance
Frequently Asked Questions
Can taking supplements like CoQ10 or DHEA improve my egg quality after 42?
There is no reliable evidence that CoQ10 or DHEA restores age-related chromosomal competence or reliably improves live birth. ESHRE does not recommend DHEA or antioxidant add-ons as routine fertility treatments. Do not start either supplement without discussing the indication, safety, and interactions with the treating clinician. ESHRE add-on guidance
What is the maximum age a woman can attempt IVF with her own eggs in Turkey?
The regulation text cited above does not state one simple upper age ceiling for IVF using autologous eggs. The practical decision still depends on current legal eligibility, medical safety, and informed consent between the patient and physician.
Why do some clinics advertise 70% IVF success for women in their 40s?
High percentages may describe a different endpoint, such as donor-egg treatment, a cumulative rate, a biochemical pregnancy, or outcomes after transfer of a selected euploid embryo. Ask which patients were included, what the denominator was, and whether the result was live birth per intended retrieval using the patient’s own eggs.
If my AMH is very low, is IVF still worth trying at 41 or 43?
Low AMH often predicts fewer oocytes per retrieval, but it does not by itself mean that IVF is impossible. An initial cycle may provide information about ovarian response, but it cannot give a definitive forecast of future live birth. The decision should be based on the full clinical picture.
What are the maternal health risks of getting pregnant after 45?
Pregnancy at older ages is associated with higher risks of gestational hypertension, preeclampsia, gestational diabetes, placental complications, and caesarean delivery. A pre-pregnancy health assessment—including cardiovascular and metabolic evaluation—is important before treatment is planned. ACOG guidance
Sources
- Practice Committee of the American Society for Reproductive Medicine. “Testing and interpreting measures of ovarian reserve: a committee opinion.” Fertility and Sterility 114.6 (2020): 1151-1157. ASRM
- Society for Assisted Reproductive Technology (SART). “National Summary Report: Preliminary Clinic Summary Report.” (2022). SART
- Centers for Disease Control and Prevention. “ART Success Rates.” (2022 national data). CDC
- European IVF-Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). “ART in Europe, 2019: results generated from European registries by ESHRE.” Human Reproduction 38.12 (2023): 2321-2338. ESHRE
- Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. “The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion.” Fertility and Sterility 122.3 (2024): 421-434. ASRM · DOI: 10.1016/j.fertnstert.2024.04.013
- Franasiak JM, Forman EJ, Hong KH, et al. “The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening.” Fertility and Sterility 101.3 (2014): 656-663. PubMed
- European Society of Human Reproduction and Embryology. “Good practice recommendations on add-ons in reproductive medicine.” (2023). ESHRE
- American College of Obstetricians and Gynecologists. “Pregnancy at Age 35 Years or Older.” (2022). ACOG
- Republic of Türkiye, Ministry of Health. “Assisted Reproduction Treatment Practices and Centres Regulation.” Mevzuat
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.